Abstract
Description
The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma,
Biotech and Diagnostics report provides comprehensive understanding and
unprecedented access to the co-promotion and co-marketing partnering
agreements entered into by the worlds leading healthcare companies.
Revised and updated 7th edition, includes:
- Trends in co-promotion and co-marketing deals
- Co-promotion and co-marketing agreement structure
- Co-promotion and co-marketing contract documents
- Top co-promotion deals by value
- Top co-marketing deals by value
- Most active co-promotion dealmakers
- Most active co-marketing dealmakers
This report provides details of the latest co-promotion and co-marketing
agreements announced in the pharmaceutical, biotechnology and diagnostic
sectors.
Fully revised and updated, the report provides details of co-promotion and
co-marketing agreements from 2007 to early 2012.
The report provides a detailed understanding and analysis of how and why
companies enter co-promotion and co-marketing deals. The majority of deals are
multicomponent whereby the licensor retains either a right or option to
co-promote/market the resultant product of the research collaboration. There
are also numerous pure co-promotion/marketing deals whereby the products
originator takes on a co-promotion/marketing partner in order to maximize a
products presence in the marketplace.
Understanding the flexibility of a prospective partner's negotiated deals
terms provides critical insight into the negotiation process in terms of what
you can expect to achieve during the negotiation of terms. Whilst many smaller
companies will be seeking details of the payments clauses, the devil is in the
detail in terms of how payments are triggered - contract documents provide
this insight where press releases and databases do not.
This report contains over 1,000 links to online copies of actual co-promotion
and co-marketing contract documents as submitted to the Securities Exchange
Commission by biopharma companies and their partners.
Contract documents provide the answers to numerous questions about a
prospective partner's flexibility on a wide range of important issues, many of
which will have a significant impact on each party's ability to derive value
from the deal.
The initial chapters of this report provide an orientation of co-promotion and
co-marketing dealmaking and business activities. Chapter 1 provides an
introduction to the report, whilst chapter 2 provides an analysis of the
trends in co-promotion and co-marketing as well as a discussion on the merits
of each type of deal.
Chapters 3 and 4 provide an overview of the structure of co-promotion and
co-marketing deals, respectively. Each chapter includes numerous case studies
to enable understanding of both pure co-promotion/marketing deals and
multicomponent deals where co-promotion/marketing forms a part.
Chapters 5 and 6 provide a review of the leading co-promotion and co-marketing
deals since 2007, respectively. Deals are listed by headline value, signed by
bigpharma, most active bigpharma, and most active of all biopharma companies.
Where the deal has an agreement contract published at the SEC a link provides
online access to the contract via the Current Agreements deals and alliances
database.
Chapter 7 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary followed by a comprehensive listing of co-promotion and
co-marketing contract deals available in the public domain. Where available,
each deal title links via Current Agreements deals and alliances database to
an online version of the actual contract document, providing easy access to
each contract document on demand.
Chapters 8 and 9 provide a comprehensive and detailed review of co-promotion
and co-marketing deals signed and announced since 2007. Each chapter is
organized by A-Z, stage of development at signing, and therapeutic area. Each
deal title links via Weblink to an online version of the actual contract
document, providing easy access to each contract document on demand.
The report also includes numerous table and figures that illustrate the trends
and activities in co-promotion and co-marketing dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs
to know about co-promotion and co-marketing as an opportunity to participate
in the commercialization of either candidate compounds in development or
products already on the market.
In addition, a comprehensive appendix is provided organized by co promotion
and co marketing partnering company A-Z , stage of development, therapeutic
target, technology type and deal type definitions. Each deal title links via
Weblink to an online version of the deal record and where available, the
contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs
to know about partnering in the research, development and commercialization of
antibody technologies and products.
Key benefits
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma,
Biotech and Diagnostics provides the reader with the following key benefits:
- In-depth understanding of co-promotion and co-marketing deal trends since
2007
- Analysis of the structure of co-promotion and co-marketing agreements with
numerous real life case studies
- Comprehensive access to over 1,000 actual co-promotion and co-marketing
deals entered into by the world's biopharma companies
- Detailed access to actual co-promotion and co-marketing contracts entered
into by the leading fifty bigpharma companies
- Insight into the terms included in a co-promotion and co-marketing
agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
Report scope
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma,
Biotech and Diagnostics is intended to provide the reader with an in-depth
understanding of the co-promotion and co-marketing trends and structure of
deals entered into by leading biopharma companies worldwide.
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma,
Biotech and Diagnostics includes:
- Trends in co-promotion and co-marketing dealmaking in the biopharma
industry since 2007
- Analysis of co-promotion and co-marketing deal structure Case studies of
real-life co-promotion and co-marketing deals
- Access to over 1,000 co-promotion and co-marketing deal records
- The leading co-promotion and co-marketing deals by value since 2007
- Most active co-promotion and co-marketing dealmakers since 2007
- The leading co-promotion and co-marketing partnering resources
In Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma,
Biotech and Diagnostics , the available contracts are listed by:
- Company A-Z Headline value
- Stage of development at signing
- Therapeutic area
Each deal title links via weblink to an online version of deal record as found
in the Current Agreements deals and alliances database, providing easy access
to each deal record on demand.
The Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma,
Biotech and Diagnostics report provides comprehensive access to available deal
records for over 1,000 co-promotion and co-marketing deals.
Analyzing actual contract agreements allows assessment of the following:
- What are the precise co-promotion and co-marketing rights granted or
optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma,
Biotech and Diagnostics provides the reader with the following key benefits:
- In-depth understanding of co-promotion and co-marketing deal trends since
2007
- Analysis of the structure of co-promotion and co-marketing agreements with
numerous real life case studies
- Comprehensive access to over 1,000 actual co-promotion and co-marketing
deals entered into by the world's biopharma companies
- Detailed access to actual co-promotion and co-marketing contracts entered
into by the leading fifty bigpharma companies
- Insight into the terms included in a co-promotion and co-marketing
agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms
for partner companies
Table of Contents
Executive Summary
Chapter 1 - Introduction Chapter
- 2.1. Introduction
- 2.2. Difference between co-promotion and co-marketing deals
- 2.3. Trends in co-promotion deals since 2007
- 2.4. Trends in co-marketing deals since 2007
- 2.4.1. When co-marketing can be useful
- 2.4.2. When co-marketing is the only option
- 2.5. Pure deals and multi-component deals
- 2.5.1. Attributes of pure co-promotion deals
- 2.5.2. Attributes of co-promotion in multi-component deals
- 2.6. Reasons for including co-promotion options in a deal
- 2.7. Uptake of co-promotion rights
- 2.8. Co-promotion rights as bargaining chips
- 2.9. Aligning partners to make the co-promote work
- 2.10 The future of co-promotion as part of multicomponent deals
Chapter 3 - Overview of co-promotion deal structure
- 3.1. Introduction
- 3.2. Pure versus multi-component co-promotion deals
- 3.3. Pure co-promotion agreement structure
- 3.3.1. Example co-promotion agreements
- 3.3.1.a. Case study 1: Allergan - MAP Pharmaceuticals - January 2011
- 3.3.1.b. Case study 2: Wyeth - Impax Laboratories - July 2008
- 3.4. Co-promotion rights as part of a wider alliance agreement
- 3.4.1. Example co-promotion option clauses
- 3.4.1.a. Case study 3: GlaxoSmithKline - Dynavax Technologies - Dec
2008
- 3.4.1.b. Case study 4: Astellas - Maxygen - September 2008
- 3.4.2. Example co-promotion right clauses
- 3.4.2.a. Case study 5: Takeda - Orexigen - September 2010
- 3.4.2.b. Case study 6: Merck - Ariad - July 2007
- 3.5. Embedded co-promotion rights enabling third party engagement
- 3.5.1. Example co-promotion clauses enabling third party engagement
- 3.5.1.a. Case study 7: Astellas - Ambit Biosciences - December 2009
Chapter 4 - Overview of co-marketing deal structure
- 4.2. Co-marketing agreement structure
- 4.2.1. Example co-marketing agreements
- 4.2.1.a. Case study 8: St Jude Medical - Cambridge Heart - July 2008
- 4.3. Co-marketing rights as part of a wider alliance agreement
- 4.3.1. Example co-marketing right clauses
- 4.3.1.a. Case study 9: Lundbeck - Myriad Genetics - May 2008
Chapter 5 - Leading co-promotion deals
- 5.1. Introduction
- 5.2. Top co-promotion deals by value
- 5.3. Most active co-promotion dealmakers
- 5.4. Bigpharma co-promotion deal activity
Chapter 6 - Leading co-marketing deals
- 6.1. Introduction
- 6.2. Top co-marketing deals by value
- 6.3. Top co-marketing deals signed by bigpharma
- 6.4. Most active co-marketing dealmakers
- 6.5. Bigpharma co-marketing deal activity
Chapter 7 - Bigpharma co-promotion and co-marketing deals
- 7.1. Introduction
- 7.2. How to use co-promotion and co-marketing deals
- 7.3. Company co-promotion and co-marketing agreement listings
Chapter 8 - Co-promotion agreement directory 2007-2012
- 8.1. Introduction
- 8.2. Company A-Z
- 8.3. By therapy area
- Anaesthetics
- Cardiovascular
- Central Nervous System
- Dental
- Dermatology
- Gastrointestinal
- Genetic disorders
- Genitourinary
- Hematology
- Hospital care
- Immunology
- Infectives
- Metabolic
- Musculoskeletal
- Oncology
- Ophthalmics
- Pediatrics
- Respiratory
- 8.4. By stage of development at signing
- Discovery
- Formulation
- Marketed
- Phase I
- Phase II
- Phase III
- Preclinical
- Regulatory
Chapter 9 - Co-marketing agreement directory 2007-2012
- 9.2. Company A-Z
- Adolor
- Alnylam Pharmaceuticals
- Biovail
- Cambridge Heart
- Columbia Laboratories
- Cortex Pharmaceuticals
- DoctorDirectory
- Eisai
- Embryome Sciences
- Galderma
- GlaxoSmithKline
- Hitachi Chemical
- Lundbeck
- Merck & Co
- MiddleBrook Pharmaceutical
- Millipore
- Myriad Genetics
- NovaBay Pharmaceuticals
- PharmaBio
- Procter & Gamble Pharmaceuticals
- Response Genetics
- Roche
- Salix Pharmaceuticals
- Sanofi-Aventis
- Senetek
- St Jude Medical
- SurModics
- Triax
- Warner Chilcott
- 9.3. By therapy area
- Cardiovascular
- Central Nervous System
- Dermatology
- Infectives
- Metabolic
- Oncology
- Ophthalmics
- Respiratory
- 9.4. By stage of development at signing
- Discovery
- Marketed
- Phase II
- Phase III
- Preclinical
- About Wildwood Ventures
- Current Partnering
- Current Agreements
- Current Reports
- Recent report titles from CurrentPartnering
- Order Form - Reports
Appendices
- Appendix A1: Co promotion dealmaking- by companies A-Z
- Appendix A2: Co promotion dealmaking- by stage of development
- Appendix A3: Co promotion dealmaking- by therapeutic target
- Appendix A4: Co promotion dealmaking- by technology type
- Appendix B1: Co marketing dealmaking- by companies A-Z
- Appendix B2: Co marketing dealmaking- by stage of development
- Appendix B3: Co marketing dealmaking- by therapeutic target
- Appendix B4: Co marketing dealmaking- by technology type
TABLE OF FIGURES
- Figure 1: Definition of co-promotion and co-marketing
- Figure 2: Trends in co-promotion deal announcements, 2007-2012
- Figure 3: Co-promotion deals signed at each phase of development, 2007-2012
- Figure 4: Trends in co-marketing deal announcements, 2007-2012
- Figure 5: Co-marketing deals signed at what phase of development, 2007-2012
- Figure 6: Situations where co-marketing can prove useful
- Figure 7: Pure versus multi-component co-promotion deal announcements,
2007-2012
- Figure 8: Stage of development at which pure and multi-component
co-promotion deals are announced 2000-2012
- Figure 9: Pure versus multi-component co-marketing deal announcements,
2007-2012
- Figure 10: Stage of development at which pure and multi-component
co-marketing deals are announced 2000-2012
- Figure 11: Key components of a pure co-promotion deal
- Figure 12: Key components of a multi-component co-promotion deal
- Figure 13: Example deals where co-promotion options have been actively
exercised, since 2000
- Figure 14: Issues in implementing co-promotion agreements
- Figure 15: Co-promotion agreements - what should a contract include?
- Figure 16: Components of the co-promotion deal structure
- Figure 17: Components of the co-marketing deal structure
- Figure 18: Top co-promotion deals by value since 2007
- Figure 20: Most active co-promotion dealmakers 2007-2012
- Figure 21: Bigpharma - top 50 - co-promotion deals 2007 to 2012
- Figure 22: Bigpharma co-promotion deal frequency - 2007 to 2012
- Figure 23: Top co-marketing deals by value since 2007
- Figure 24: Top co-marketing deals involving bigpharma by value since 2007
- Figure 25: Most active co-marketing dealmakers 2007-2012
- Figure 26: Bigpharma - top 50 - co-marketing deals since 2007
- Figure 27: Bigpharma co-marketing deal frequency - 2007 to 2012
Co-promotion and Co-marketing Partnering Terms and Agreements published by Current Partnering, a division of Wildwood Ventures Limited in January 7, 2013. This report consists of 1037 Pages and the price starts from US $ 2695.
The contents of this page may be different from the latest version. Please contact us for details.
